Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies. This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes: - the new IMWG SLiM CRAB criteria - the latest advances in diagnostic tests and imaging - cytogenetics and genetic profiling - induction therapy prior to SCT - new lenalidomide- and bortezomib-based regimens - second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments. This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice. Contents: • Epidemiology and etiology Predisposing conditions associated with MM • Pathophysiology of MM and MGUS • Diagnosis, staging and monitoring of multiple myeloma • Genetics and multiple myeloma • Treatment of newly diagnosed multiple myeloma • Stem cell transplantation in multiple myeloma • Relapsed and refractory multiple myeloma • Bone disease and renal complications • AL amyloidosis • Rare plasma cell dyscrasias • Supportive care

Information + Taking Control = Best Outcome is the theme running through this short, superbly illustrated workbook, which is designed to help patients equip themselves with the best information about myeloma. Starting with a simple overview of the biology of the disease, this comprehensive resource will also help patients to understand the type of myeloma that they have, the remitting-relapsing nature of the disease, and the signs and symptoms they are likely to experience. 'Fast Facts: Myeloma for Patients and their Supporters' takes patients through the initial treatment options and their side effects, what to expect if they have stem cell transplantation, and how they will be treated when their symptoms return. The final sections will help patients understand what supportive care options are available to them, and provide an insight into the latest myeloma research, which is progressing on many fronts. With FastTests to test patients' understanding of their condition throughout, and plenty of space for patients to write their own notes, this concise, easy-to-read resource will help patients get organized so that they are better equipped to ask the right questions and have more meaningful discussions with their doctors and nurses. Ultimately, it will help them make the best decisions about their care. Contents: • Information + Taking Control = Best Outcome • What is myeloma? • Who gets myeloma and why? • How is myeloma diagnosed? • What type of myeloma do I have? • What are the effects of myeloma? • What is staging and why is it done? • What initial treatment will I receive? • Stem cell transplantation • Monitoring the effects of therapy • Treatment when myeloma returns • Supportive care • Research to follow and support • Useful resources

Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.

Multiple Myeloma accounts for approximately 0.8% of cancers worldwide, with about 114 000 new cases each year. Rapid progress is being made in the development of new treatments and, although myeloma is incurable at present, survival has almost tripled over the past 10 years and it is now projected that a third of patients will survive more than 10 years after diagnosis.Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias emphasizes the importance of early diagnosis for a favourable outcome, covers the ever-increasing role of genetics in diagnosis and treatment, and discusses new and gold-standard treatments. A chapter on supportive care also features and briefs the healthcare professional on long-term outcomes and quality of life issues. Primarily intended for primary care providers, specialist nurses, junior doctors and allied healthcare professionals, this highly readable resource provides a comprehensive overview of myeloma and other plasma cell dyscrasias, from bench to bedside, putting the pathogenesis, diagnosis and treatment of these disorders in the context of daily clinical practice.

This two-part issue, edited by Dr. Rathan Subramaniam, reviews current clinical information in "PET/CT and Patient Outcomes." In Part I of this issue, articles will include: Head and Neck Cancer, Lung Cancer, Esophageal Cancer, Breast Cancer, Lymphoma, Melanoma, Prostate Cancer, Multiple Myeloma, Thyroid Cancer, Radiation Therapy Planning, Infection/Inflammation, Colorectal Cancer, and more!

Myelomas: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Myelomas: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Myelomas: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

The Manual of Clinical Oncology, Ninth Edition, published with the International Union Against Cancer (UICC), provides a concise, accessible and feasible reference covering state of art multidisciplinary clinical oncology in order to meet the needs of clinicians caring for cancer patients throughout the world. Edited by world-renowned practising oncologists and written by key opinion leaders, this book contains authoritative and up-to-date information on cancer detection, diagnosis and treatment alongside topics such as survivorship, special populations and palliative care. Remodelled and revised for the ninth edition to provide practical information to oncology workers, the UICC Manual of Clinical Oncology is structured in two parts. Part 1 covers general principles of cancer diagnosis and management with additional attention to special settings in oncology, including supportive care and survivorship, and Part 2 covers site-specific multidisciplinary cancer management. The edition includes up-to-date summaries of all treatment modalities (medical, surgical and radiation) for all tumour sites. It also contains the latest TNM classifications outlined in the TNM Classification of Malignant Tumours. The ninth edition includes: Practical presentation with bullet points, tables, and flow charts intended to facilitate quick reference for day-to-day clinical practice in busy oncology environments, Representation of multidisciplinary care for site specific management, Evidence-based approaches to management, including specific treatment recommendations and investigations guided by clinical practice guidelines, State of art evidence-based recommendations that take into consideration the lack of availability of certain medications or resources, as well as practice variations, in different and remote regions of the world, and Contemporary topics on cancer treatment, such as cancer informatics, evidence levels, principles of prognostication, survivorship and cancer in pregnancy. Oncologists, oncologists-in-training, nurses working with cancer patients and other health professionals responsible for treating and caring for those with cancers will find the UICC Manual of Clinical Oncology an indispensable and comprehensive resource.

NEW! UPDATED 2019 Official Code set reflects the latest ICD-10 codes needed for diagnosis coding.

This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenström’s macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.